• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page
Interesting Myeloma Articles September 2021

Interesting Myeloma Articles September 2021

by MM360 Staff | Sep 28, 2021 | Featured News, Myeloma News

Here are some interesting Myeloma journal articles and some of the most discussed on Twitter for September 2021. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to whites: a propensity-score...
Interesting Myeloma Articles September 2021

Top Myeloma Journal Articles for the Week of June 28, 2021

by MM360 Staff | Jul 7, 2021 | Featured News

  Here are the top journal articles from the week of June 24, 2021 as selected by the MYELOMA360 staff.   First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness...

Ask the Nurse – Treatment practicalities and decision making in Myeloma

by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News

Several drugs and drug combinations are used to treat myeloma. The drugs have varying side effects, work differently and are given in different ways. This complexity can make it challenging for patients to decide which treatment option is right for them. As a result,...

NICE issues draft ‘no’ on first quadruplet combination for England and Wales

by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News

The post NICE issues draft ‘no’ on first quadruplet combination for England and Wales appeared first on Myeloma UK.

Charity collaborative announces investment of £800K in vaccine efficacy research

by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News

The Blood Cancer UK Vaccine Research Collaborative has announced funding for nine research projects, worth £800K in total, that will look at covid vaccine effectiveness in people with blood cancer. Early data suggests that the coronavirus vaccines may not work as well...

Blood Type O Lowers Myeloma Risk, But Outcomes Typically Worse

by MM360 Staff | Jun 10, 2021 | Featured News, Myeloma News

People with blood type O are significantly less likely to develop multiple myeloma, but those who do are likely to have more aggressive disease and poorer survival outcomes, a study found. The study, “Effect of the ABO blood groups on the development, clinical...
« Older Entries

Recent Content

  • Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
  • Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
  • Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
  • Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
  • Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
  • ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
  • Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma
  • Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression
  • Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma
  • Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT